

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:  
DAVID R. MARSH  
ARNOLD & PORTER LLP  
555 TWELFTH STREET, N.W.  
WASHINGTON, D.C., DC 20004

# PCT

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Applicant's or agent's file reference 19025.021		Date of mailing (day/month/year) <b>06 NOV 2007</b>
<b>FOR FURTHER ACTION</b> See paragraph 2 below		
International application No. PCT/US04/20751	International filing date (day/month/year) 28 June 2004 (28.06.2004)	Priority date (day/month/year) 24 May 2004 (24.05.2004)
International Patent Classification (IPC) or both national classification and IPC IPC(8): C12Q 1/68( 2006.01);C07H 21/04 USPC: 435/6,69.1,320.1,325;530/350;536/23.5		
Applicant PTC THERAPEUTICS		

**1. This opinion contains indications relating to the following items:**

- ☒ Box No. I      Basis of the opinion
- ☐ Box No. II      Priority
- ☐ Box No. III      Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☒ Box No. IV      Lack of unity of invention
- ☒ Box No. V      Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI      Certain documents cited
- ☐ Box No. VII      Certain defects in the international application
- ☐ Box No. VIII      Certain observations on the international application

**2. FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

**3. For further details, see notes to Form PCT/ISA/220.**

Name and mailing address of the ISA/ US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Date of completion of this opinion 15 October 2007 (15.10.2007)	Authorized officer Stephanie K. Mummert, Ph.D. Telephone No. 571-272-0872
--	--	---

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/20751

**Box No. I Basis of this opinion**

1. With regard to the **language**, this opinion has been established on the basis of:

- ☒ the international application in the language in which it was filed
- ☐ a translation of the international application into \_\_\_\_\_, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).

2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:

a. type of material

- ☒ a sequence listing
- ☐ table(s) related to the sequence listing

b. format of material

- ☒ on paper
- ☒ in electronic form

c. time of filing/furnishing

- ☒ contained in the international application as filed.
- ☒ filed together with the international application in electronic form.
- ☐ furnished subsequently to this Authority for the purposes of search.

3. ☒ In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

4. Additional comments:

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/US04/20751

Box No. IV Lack of unity of invention

1. ☒ In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has, within the applicable time limit:
- ☐ paid additional fees
  - ☐ paid additional fees under protest and, where applicable, the protest fee
  - ☐ paid additional fees under protest but the applicable protest fee was not paid
  - ☒ not paid additional fees
2. ☐ This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applicant to pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 13.3 is
- ☐ complied with
  - ☒ not complied with for the following reasons:  
See the lack of unity section of the International Search Report (Form PCT/ISA/210)

4. Consequently, this opinion has been established in respect of the following parts of the international application:
- ☐ all parts.
  - ☒ the parts relating to claims Nos. 1-27

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US04/20751

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims <u>NONE</u>	YES
	Claims <u>1-27</u>	NO
Inventive step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-27</u>	NO
Industrial applicability (IA)	Claims <u>1-27</u>	YES
	Claims <u>NONE</u>	NO

2. Citations and explanations:

Please See Continuation Sheet

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US04/20751

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

V. 2. Citations and Explanations:

*Claim Interpretation*

The term 'in an absence of SEQ ID NO:4' is being given the broadest reasonable interpretation in light of the specification. The term is not explicitly defined in the spec. Instead, SEQ ID NO:4 is referred to as NeRP and as "SEQ ID NO:4 sets forth a NeRP1, a 336 nucleotide region of a VEGF 5'UTR" (p. 8 of specification) and it is noted that searching the sequence against nucleotide databases does not necessarily provide art where the sequence is deleted. However, the nucleotide boundaries of SEQ ID NO:4 are not established relative to the context of the overall full-length VEGF 5' UTR. Therefore, without clear nucleotide boundaries of the region comprising SEQ ID NO:4, the term is being interpreted as reading on art where the 5' UTR is deleted partially, either at the 5' end of the UTR, the 3' end of the UTR or from the middle.

The term 'UTR having a NeRP1 (SEQ ID NO: 4)' is also being given the broadest reasonable interpretation in light of the specification. As noted above, the limitations of SEQ ID NO:4 are not clearly defined. The term is being interpreted as the opposite of 'in the absence of SEQ ID NO:4' and is interpreted as reading on art where a full length VEGF 5' UTR is present in the nucleotide construct.

The limitations of SEQ ID NO:3 are also not explicitly defined in the spec. Instead, SEQ ID NO:3 is referred to as PTCRE1 and as "SEQ ID NO:3 sets forth a PTCRE1, a 702 nucleotide region of VEGF 5'UTR" (p. 8 of specification) and like SEQ ID NO:4, the nucleotide boundaries of SEQ ID NO:3 are not established relative to the full-length 5' UTR and searching the sequence against nucleotide databases does not necessarily provide art where the sequence is deleted. Therefore, the term 'wherein the PTCRE is not SEQ ID NO:3' is being interpreted as reading on art where the 5' UTR is partially deleted, either at the 5' end of the UTR, the 3' end of the UTR or from the middle. And where SEQ ID NO:3 is not described either way, or particularly where the sequence comprising 'SEQ ID NO:3, a fragment thereof, or a complement of either' is being interpreted as reading on art where the full length 5' UTR is present in the nucleotide construct.

Claims 1-27 lack novelty under PCT Article 33(2) as being anticipated by Forsythe et al. (Molecular and Cellular Biology, 1996, vol. 16, no. 9, p. 4604-4613). Forsythe teaches a method of analyzing the effect of hypoxia inducible factor on the expression of VEGF (Abstract).

With regard to claims 1-10 and 14, Forsythe teaches a variety of nucleic acid constructs and nucleic acids that comprise a nucleic acid encoding a reporter polypeptide, wherein the nucleic acid sequence encoding a reporter polypeptide is operably linked to a NeRP, said NeRP (SEQ ID NO:4) is operably linked to a PTCRE (wherein said PTCRE is not SEQ ID NO:3), and expression of said reporter polypeptide is capable of being modulated relative to in an absence of said NeRP (Figure 1A, where a variety of constructs comprising deletions of the 5' UTR, and therefore in the absence of SEQ ID NO:3; see also p. 4605, col. 1, 'reporter plasmid constructs')

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US04/20751

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

heading, where the UTR is linked to luciferase reporter gene).

With regard to claims 11-13 and 15-21, Forsythe teaches a reporter construct wherein said VEGF 5' UTR is in an absence of SEQ ID NO:4 and contains an intron (Figure 1A, where a variety of constructs comprising deletions of the 5' UTR, and therefore in the absence of SEQ ID NO:4; see also p. 4605, col. 1, 'reporter plasmid constructs' heading, where the UTR is linked either to VEGF ORF or luciferase reporter gene), wherein these constructs produce polypeptides (see also p. 4605, col. 1, 'reporter plasmid constructs' heading, where the UTR is linked either to VEGF ORF or luciferase reporter gene), and are produced in vitro (p. 4605, where the constructs are produced in vitro, see 'transient expression assays' heading).

With regard to claims 22-24, Forsythe teaches a nucleic acid molecule that comprises 95-99% sequence identity with a nucleic acid molecule of SEQ ID NO:3, a fragment thereof or a complement of either, consists of SEQ ID NO:3 or a fragment or complement thereof, or consists of a nucleic acid linked to a reporter polypeptide wherein the nucleic acid sequence consists of SEQ ID NO:3 (Figure 1A, where a variety of constructs comprising deletions and full length versions, see KpnI of the 5' UTR, and therefore comprising SEQ ID NO:3).

With regard to claims 23-27, Forsythe teaches a nucleic acid molecule that comprises 95-99% sequence identity with a nucleic acid molecule of SEQ ID NO:4, a fragment thereof or a complement of either, consists of SEQ ID NO:4 or a fragment or complement thereof, or consists of a nucleic acid linked to a reporter polypeptide wherein the nucleic acid sequence consists of SEQ ID NO:4 (Figure 1A, where a variety of constructs comprising deletions and full length versions, see KpnI of the 5' UTR, and therefore comprising SEQ ID NO:4).

Claims 22-27 lack novelty under PCT Article 33(2) as being anticipated by Kamiya et al. (US Patent 6,057,437; May 2000) teach the specific nucleotide sequences of VEGF 3' and 5' UTR regions (Table I, col. 10).

With regard to claims 22-24, Kamiya teaches a nucleic acid molecule that comprises 95-99% sequence identity with a nucleic acid molecule of SEQ ID NO:3, a fragment thereof or a complement of either, consists of SEQ ID NO:3 or a fragment or complement thereof, or consists of a nucleic acid linked to a reporter polypeptide wherein the nucleic acid sequence consists of SEQ ID NO:3 (Table I, col. 10, see sequence alignment below).

```
Qy      1  TCCAGAGAGAGTTCGAGGAAGAGAGAGACGGGGTCAGAGAGAGCGCGCGGGCGTGCGAGC  60
      |||
Db      337 TCCAGAGAGAGTTCGAGGAAGAGAGAGACGGGGTCAGAGAGAGCGCGCGGGCGTGCGAGC  396

Qy      61  AGCGAAAGCGACAGGGGCAAAGTGAGTGACCTGCTTTTGGGGGTGACCGCGGAGCGCGG  120
      |||
Db      397 AGCGAAAGCGACAGGGGCAAAGTGAGTGACCTGCTTTTGGGGGTGACCGCGGAGCGCGG  456

Qy      121 CGTGAGCCCTCCCGCTTGGGATCCCGCAGCTGACCACTGCGCTGAOGGACAGACAGACA  180
      |||
Db      457 CGTGAGCCCTCCCGCTTGGGATCCCGCAGCTGACCACTGCGCTGAOGGACAGACAGACA  516

Qy      181 GACACGCGCCCCAGCCCCAGCTACCACTCTCTCCCGCGCGCGCGGACAGTGAGCGCG  240
      |||
Db      517 GACACGCGCCCCAGCCCCAGCTACCACTCTCTCCCGCGCGCGCGGACAGTGAGCGCG  576

Qy      241 GCAGCGAGCGCGCGGCGAGGGGCGGAGCCCGCGCCCGGAGGCGGGGTGAGGGGGTCTGGG  300
      |||
Db      577 GCAGCGAGCGCGCGGCGAGGGGCGGAGCCCGCGCCCGGAGGCGGGGTGAGGGGGTCTGGG  636

Qy      301 GCTCGCGCGTGCCTGAAACTTTTGGTCCAACCTTCTGGGCTGTTCTCGCTTCGGAGGA  360
      |||
Db      637 GCTCGCGCGTGCCTGAAACTTTTGGTCCAACCTTCTGGGCTGTTCTCGCTTCGGAGGA  696

Qy      361 GCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAGTGCTAGCTCGGGC  420
      |||
Db      697 GCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAGTGCTAGCTCGGGC  756

Qy      421 CGGGAGGAGCCCGCAGCCGAGGAGGGGAGGAGGAAGAAGAGAGGAAGAGGAGAGGGGG  480
      |||
Db      757 CGGGAGGAGCCCGCAGCCGAGGAGGGGAGGAGGAAGAAGAGAGGAAGAGGAGAGGGGG  816

Qy      481 CCGCAGTGGCGACTCGGCGCTCGGAAGCCGGGCTCATGGACGGGTGAGGCGGGTGTGC  540
      |||
Db      817 CCGCAGTGGCGACTCGGCGCTCGGAAGCCGGGCTCATGGACGGGTGAGGCGGGTGTGC  876

Qy      541 GCAGACAGTGTCCAGCCGCGCGCTCCCGAGGCCCTGGCCCGGGCTCGGGCCGGGGA  600
      |||
Db      877 GCAGACAGTGTCCAGCCGCGCGCTCCCGAGGCCCTGGCCCGGGCTCGGGCCGGGGA  936

Qy      601 GGAAGAGTAGCTCGCCGAGGCGCCGAGGAGAGCGGGCCGCCACAGCCCGAGCCGGAGA  660
      |||
Db      937 GGAAGAGTAGCTCGCCGAGGCGCCGAGGAGAGCGGGCCGCCACAGCCCGAGCCGGAGA  996
```

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.  
PCT/US04/20751

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

QY 661 GGGAGCGCGAGCCGCGCCCGGCTCGGGCTCCGAAACC 702  
|||||  
Db 997 GGGAGCGCGAGCCGCGCCCGGCTCGGGCTCCGAAACC 1038

With regard to claims 23-27, Kaniya teaches a nucleic acid molecule that comprises 95-99% sequence identity with a nucleic acid molecule of SEQ ID NO:4, a fragment thereof or a complement of either, consists of SEQ ID NO:4 or a fragment or complement thereof, or consists of a nucleic acid linked to a reporter polypeptide wherein the nucleic acid sequence consists of SEQ ID NO:4 (Table 1, col. 10, see sequence alignment below).

QY 1 TCGCGGAGGCTTGGGGCAGCCGGGTAGCTCGGAGGTCGTGGCGCTGGGGCTAGCACCAG 60  
|||||  
Db 1 TCGCGGAGGCTTGGGGCAGCCGGGTAGCTCGGAGGTCGTGGCGCTGGGGCTAGCACCAG 60

QY 61 CGCTCTGTCGGGAGCGCAGCGGTTAGGTGGACCGGTCAGCGGACTCACCAGCCAGGGCG 120  
|||||  
Db 61 CGCTCTGTCGGGAGCGCAGCGGTTAGGTGGACCGGTCAGCGGACTCACCAGCCAGGGCG 120

QY 121 CTCGGTGCTGGAATTIGATATTCATTGATCCGGGTTTTATCCCTCTTCTTTTCTTAAA 180  
|||||  
Db 121 CTCGGTGCTGGAATTIGATATTCATTGATCCGGGTTTTATCCCTCTTCTTTTCTTAAA 180

QY 181 CATTITTTTTTAAACTGTATTGTTTCTCGTTTTAATTTATTTTGTCTTGCCATTCCCCA 240  
|||||  
Db 181 CATTITTTTTTAAACTGTATTGTTTCTCGTTTTAATTTATTTTGTCTTGCCATTCCCCA 240

QY 241 CTTGAATCGGGCCGACGGCTTGGGGAGATTGCTCTACTTCCCCAAATCACTGTGGATTTT 300  
|||||  
Db 241 CTTGAATCGGGCCGACGGCTTGGGGAGATTGCTCTACTTCCCCAAATCACTGTGGATTTT 300

QY 301 GGAAACCAGCAGAAAGAGGAAAGAGGTAGCAAGAGC 336  
|||||  
Db 301 GGAAACCAGCAGAAAGAGGAAAGAGGTAGCAAGAGC 336

Claims 1-27 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.